Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
基本信息
- 批准号:10684172
- 负责人:
- 金额:$ 35.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdult T-Cell Leukemia/LymphomaAffectAllelesAngiogenesis InhibitorsAnimal ModelAntisense OligonucleotidesAntiviral TherapyApoptosisBindingBiological AssayBiological MarkersBone MarrowCRISPR/Cas technologyCaspaseCell LineClinicClinicalClinical Trials NetworkClonalityClustered Regularly Interspaced Short Palindromic RepeatsCombination Drug TherapyCorrelative StudyDevelopmentDiseaseExonsGene ExpressionGene TargetingGenesGenomeGenotypeGrowthHuman T-lymphotropic virus 1IRF4 geneImidesImmuneImmunodeficient MouseIndividualInternationalInvestigational TherapiesKnock-outKnowledgeLymphoma cellMalignant NeoplasmsMature T-LymphocyteMediatingMolecularMonitorMulti-Institutional Clinical TrialMusMutateMutationNuclearPLC gamma1PathogenesisPathway interactionsPhase I Clinical TrialsPositioning AttributePrediction of Response to TherapyProliferatingProtein InhibitionProteinsReceptor SignalingRefractoryRegistriesRelapseRepressionRoleT Cell Receptor Signaling PathwayT-Cell LymphomaT-Cell ReceptorT-Cell and NK-Cell NeoplasmT-LymphocyteTestingTherapeuticTranscriptional ActivationTranslatingTransplantationTreatment EfficacyValidationViral GenomeViral OncogeneVirusantitumor effectcell immortalizationchemotherapycytotoxicexperiencegain of function mutationgene productimmunoregulationimprovedinhibitorknock-downlenalidomideleukemia/lymphomanew therapeutic targetoverexpressionparticipant enrollmentphase 1 studyphase I trialphospholipase C gammaprotein kinase C betarecruitresponsesmall hairpin RNAsuccesssynergismtargeted treatmenttherapeutic targettherapy resistanttranscription factortranscriptometranscriptome sequencingtumorigenesisubiquitin-protein ligase
项目摘要
Abstract – Inhibition of T-Cell Receptor Signaling for Treatment of Adult T-Cell Leukemia Lymphoma
Human T-cell leukemia virus type 1 (HTLV-1)-associated adult T-cell leukemia-lymphoma (ATLL) is an
aggressive lymphoproliferative malignancy. Despite aggressive chemotherapy, this disorder is fatal in almost all
individuals. Our preliminary results, and those of others, uncovered a high rate of mutations in the T-cell receptor
(TCR) signaling pathway in ATLL, with frequent mutations in phospholipase Cγ, protein kinase Cβ (PKCβ), and
caspase recruitment domain containing protein 11 (CARD11) leading to activation of transcription factors nuclear
factor κB (NFκB) and interferon-regulatory factor 4 (IRF4). We hypothesize that this pathway drives ATLL
development and/or progression and targeted therapy against this pathway will synergize with combination
chemotherapy. We also suggest that lenalidomide represses IRF4 expression in ATLL. We propose to assess:
Aim 1: Role of IRF4 activation in ATLL through RNAseq and functional analysis of IRF4-dependent gene
targets. We will also determine if repression of IRF4 mediates the cytotoxic effects of lenalidomide in ATLL.
Aim 2: Phase 1 study of lenalidomide in combination with EPOCH chemotherapy for HTLV-ATLL is
conducted through the ETCTN, and correlative studies performed in the current project to assess whether
efficacy of lenalidomide is mediated through effects on IRF4, and depend on mutations in TCR pathway
components. HTLV load, expression, and clonality assays will be used to monitor the efficacy of therapy.
Aim 3: Role of PKCβ activation in ATLL will be examined as an alternative therapeutic target, based on
sensitivity of ATLL cells to inhibitors, enzastaurin and midostaurin. We will assess whether sensitivity to these
inhibitors are affected by mutations in PKCβ or CARD11, which often co-occur in ATLL.
This study will provide in-depth knowledge of the role of TCR signaling in ATLL, and new therapeutic targets.
摘要 - 抑制T细胞受体信号用于治疗成人T细胞白血病淋巴瘤
人类T细胞白血病病毒1型(HTLV-1)相关的成人T细胞白血病 - 淋巴瘤(ATLL)是
侵略性淋巴增生性恶性肿瘤。尽管进行了积极的化学疗法,但这种疾病几乎全部致命
个人。我们的初步结果以及其他结果,发现了T细胞接收器中的高突变率
(TCR)ATLL中的信号通路,在磷脂酶Cγ,蛋白激酶Cβ(PKCβ)和
caspase募集结构域含有蛋白质11(card11),导致转录因子的激活核
因子κB(NFκB)和干扰素调节因子4(IRF4)。我们假设该途径驱动ATLL
开发和/或进展以及针对该途径的靶向疗法将与组合协同
化学疗法。我们还建议,来那捷胺反映了ATLL中的IRF4表达。我们建议评估:
AIM 1:IRF4激活在ATLL中的作用通过RNASEQ和IRF4依赖性基因的功能分析
目标。我们还将确定IRF4的表达是否介导了Lenalidomide在ATLL中的细胞毒性作用。
AIM 2:Lenalidomide与HTLV-ATLL时期化学疗法结合的1阶段研究
通过ETCTN进行的,并在当前项目中进行的正确研究,以评估是否是否
Lenalidomide的作用是通过对IRF4的影响介导的,并取决于TCR途径中的突变
成分。 HTLV负载,表达和克隆性测定将用于监测治疗的效率。
目标3:基于
ATLL细胞对抑制剂,Enzastaurin和Midostaurin的敏感性。我们将评估对这些的敏感性
抑制剂受PKCβ或Card11突变的影响,这些突变通常在ATLL中共发生。
这项研究将对TCR信号在ATLL和新的治疗靶标的作用提供深入的了解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lee Ratner其他文献
Lee Ratner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lee Ratner', 18)}}的其他基金
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
- 批准号:
10518751 - 财政年份:2022
- 资助金额:
$ 35.31万 - 项目类别:
Interaction of HTLV-1 Tax & Hbz in Transformation
HTLV-1 税的相互作用
- 批准号:
10189192 - 财政年份:2021
- 资助金额:
$ 35.31万 - 项目类别:
Role of Protein Kinase C Mutations in Adult T-Cell Leukemia
蛋白激酶 C 突变在成人 T 细胞白血病中的作用
- 批准号:
10322134 - 财政年份:2021
- 资助金额:
$ 35.31万 - 项目类别:
Interaction of HTLV-1 Tax & Hbz in Transformation
HTLV-1 税的相互作用
- 批准号:
10403617 - 财政年份:2021
- 资助金额:
$ 35.31万 - 项目类别:
Single-Cell Transcriptome & Effect of Immune Checkpoint Therapy on Kaposi Sarcoma
单细胞转录组
- 批准号:
10417051 - 财政年份:2021
- 资助金额:
$ 35.31万 - 项目类别:
Role of Protein Kinase C Mutations in Adult T-Cell Leukemia
蛋白激酶 C 突变在成人 T 细胞白血病中的作用
- 批准号:
10095197 - 财政年份:2021
- 资助金额:
$ 35.31万 - 项目类别:
相似海外基金
Pathophysiology of Adult T-cell leukemia/lymphoma
成人 T 细胞白血病/淋巴瘤的病理生理学
- 批准号:
10609828 - 财政年份:2022
- 资助金额:
$ 35.31万 - 项目类别:
Escape from CAR T surveillance through lineage plasticity
通过谱系可塑性逃避 CAR T 监控
- 批准号:
10419173 - 财政年份:2022
- 资助金额:
$ 35.31万 - 项目类别:
Pathophysiology of Adult T-cell leukemia/lymphoma
成人 T 细胞白血病/淋巴瘤的病理生理学
- 批准号:
10369933 - 财政年份:2022
- 资助金额:
$ 35.31万 - 项目类别:
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)
淋巴瘤流行病学结果 (LEO) 队列研究(补充)
- 批准号:
10626269 - 财政年份:2022
- 资助金额:
$ 35.31万 - 项目类别:
Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells
利用造血干细胞衍生的初始 CAR T 细胞利用胸腺来长期控制肿瘤
- 批准号:
10365031 - 财政年份:2022
- 资助金额:
$ 35.31万 - 项目类别: